CPT 0253U: Endometrial Receptivity Analysis (ERA) Test

CPT code 0253U designates a Proprietary Laboratory Analyses (PLA) test for the ERA® (Endometrial Receptivity Analysis) from Igenomix® USA. The assay measures RNA expression in an endometrial biopsy to identify the optimal window for embryo transfer in patients undergoing assisted reproductive treatment (ART). As a PLA code, 0253U is tied to a single manufacturer's proprietary test, which has implications for clinical adoption, billing consistency, and payer coverage determinations nationwide.

Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for endometrial receptivity testing, common billing considerations for proprietary molecular diagnostics, and the landscape of payer approaches to similar fertility-related laboratory services. The publication summarizes service type and typical site of service, highlights common modifiers used in practice, and identifies where input data was not provided.

This piece is intended for national audiences including payers, billing professionals, fertility clinicians, and laboratory administrators who need a clear, operational briefing on CPT code 0253U, its clinical purpose, and the reimbursement environment relevant to proprietary endometrial receptivity testing.

Billing Code Overview

CPT code 0253U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to the ERA® (Endometrial Receptivity Analysis) test from Igenomix® USA. The test evaluates RNA expression in an endometrial biopsy from a patient undergoing assisted reproductive treatment (ART) to determine the optimal timing for embryo transfer based on endometrial receptivity.

Service type: Molecular diagnostic laboratory test (proprietary PLA)

Typical site of service: Clinical laboratory or specialized reproductive medicine laboratory, with specimen collection performed in an outpatient reproductive endocrinology or fertility clinic.

Clinical Context

A 34-year-old woman with a history of recurrent implantation failure undergoing assisted reproductive treatment (ART) elects to have an endometrial receptivity test to optimize timing of embryo transfer. She undergoes an endometrial biopsy in the mid-luteal phase during a mock or natural cycle. The specimen is shipped to the proprietary laboratory for the ERA® (Endometrial Receptivity Analysis) assay from Igenomix® USA, which evaluates RNA expression to classify the endometrium as receptive, pre-receptive, or post-receptive. Results inform scheduling of a subsequent frozen embryo transfer during the individualized window of implantation. Typical workflow: patient counseling and consent during fertility clinic visit; cycle monitoring and timing for biopsy; outpatient endometrial biopsy performed in a clinic or ambulatory surgery center; specimen handling and courier to the manufacturer’s lab; laboratory analysis and report returned to the ordering reproductive endocrinologist; plan for embryo transfer timing adjusted based on report.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when reporting only the professional component of a test if applicable and separable from technical component.
`52`

Taxonomy Code	Specialty	Notes
`2084P0800X`	Reproductive Endocrinology & Infertility	Reproductive endocrinologists order and interpret ERA testing and perform endometrial biopsies.
`207RC0000X`	Obstetrics & Gynecology	General OB/GYNs in fertility clinics may perform biopsies and coordinate testing.
`363A00000X`	Clinical Laboratory	Laboratory specialists process samples and interface with proprietary testing labs; LTC/consult role.
`334S00000X`	Nurse Practitioner	NPs may perform outpatient biopsies and coordinate specimen handling under clinic protocols.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`N97.9`	Female infertility, unspecified	Common indication for ERA testing when planning embryo transfer in ART.
`N97.0`	Female infertility associated with anovulation	ERA may be used in infertility evaluations when timing of implantation is a concern.
`N97.1`	Female infertility due to tubal origin	Patients with tubal factor infertility may still undergo ERA when planning embryo transfer with IVF.
`N97.8`	Other female infertility	ERA testing considered in varied infertility etiologies, including unexplained implantation failure.
`Z31.84`	Encounter for fertility preservation procedures	Relevant when endometrial receptivity assessment is part of fertility planning and preservation protocols.
`N97.2`	Female infertility of uterine origin	Uterine factor infertility patients may have ERA to assess endometrial receptivity prior to transfer.
`O09.89`	Supervision of other high-risk pregnancy	May be used in documentation when ART and implantation timing impact high-risk pregnancy planning.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`58100`	Endometrial sampling (biopsy) without cervical dilation, any method	Often performed to obtain the endometrial tissue sample submitted for ERA testing.
`58300`	Insertion of intrauterine device (IUD) — diagnostic codes often not related; included for procedural context	Not typically related; listed here only when intrauterine procedures coincide with fertility care.
`88185`	Cytopathology, smears, or liquid-based cytology; automated thin-layer preparation, screening and interpretation	May be used in clinics for parallel endometrial cytology but not a substitute for molecular ERA testing.
`0191U`	Proprietary Laboratory Analyses (example PLA) — placeholder for other proprietary reproductive molecular assays	Represents similar PLA tests used in ART workflows; used for comparison to ERA testing.
`86850`	Tissue examination by gross and microscopic evaluation (pathology)	May be used if the biopsy tissue undergoes histopathologic evaluation in addition to molecular testing.

OpenPayer

Summary & Overview